BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31423576)

  • 1. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.
    Lockmer S; Ren W; Brodtkorb M; Østenstad B; Wahlin BE; Pan-Hammarström Q; Kimby E
    Br J Haematol; 2020 Jan; 188(2):259-267. PubMed ID: 31423576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
    Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
    Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy.
    Rodríguez-Sevilla JJ; Fernández-Rodríguez C; Bento L; Diez-Feijóo R; Pinzón S; Gibert J; Fernández-Ibarrondo L; Lafuente M; Ferrer A; Sánchez-González B; Gimeno E; Sainz J; Ramos R; García JF; Colomo L; Bellosillo B; Gutiérrez A; Salar A
    Blood Adv; 2023 Apr; 7(8):1606-1614. PubMed ID: 36260737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy.
    Kimby E; Lockmer S; Holte H; Hagberg H; Wahlin BE; Brown P; Østenstad B
    Br J Haematol; 2020 Dec; 191(5):738-747. PubMed ID: 32410260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients.
    Formica V; Norman AR; Cunningham D; Wotherspoon A; Oates J; Chong G
    Acta Haematol; 2009; 122(4):193-9. PubMed ID: 19887775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome.
    Buske C; Hoster E; Dreyling M; Hasford J; Unterhalt M; Hiddemann W
    Blood; 2006 Sep; 108(5):1504-8. PubMed ID: 16690968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in follicular lymphoma: the importance of beta-2 microglobulin.
    Cánovas A; Alonso JJ; Barreiro G; Aguirre C
    Tumori; 2010; 96(1):117-21. PubMed ID: 20437868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
    Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
    Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
    Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
    Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.
    Sohani AR; Maurer MJ; Giri S; Pitcher B; Chadburn A; Said JW; Bartlett NL; Czuczman MS; Martin P; Rosenbaum CA; Jung SH; Leonard JP; Cheson BD; Hsi ED
    Am J Surg Pathol; 2021 Mar; 45(3):384-393. PubMed ID: 33136585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment.
    Arcaini L; Colombo N; Passamonti F; Burcheri S; Orlandi E; Brusamolino E; Della Porta M; Rumi E; Montanari F; Pascutto C; Paulli M; Lazzarino M
    Leuk Res; 2006 Mar; 30(3):277-82. PubMed ID: 16112730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic ability of five clinical risk scores in follicular lymphoma: A single-center evaluation.
    Mozas P; Rivero A; Rivas-Delgado A; Correa JG; Condom M; Nadeu F; Giné E; Delgado J; Villamor N; Campo E; Magnano L; López-Guillermo A
    Hematol Oncol; 2021 Dec; 39(5):639-649. PubMed ID: 34494300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.
    Mottok A; Jurinovic V; Farinha P; Rosenwald A; Leich E; Ott G; Horn H; Klapper W; Boesl M; Hiddemann W; Steidl C; Connors JM; Sehn LH; Gascoyne RD; Hoster E; Weigert O; Kridel R
    Blood; 2018 Jan; 131(2):226-235. PubMed ID: 29122756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models.
    Alig S; Jurinovic V; Shahrokh Esfahani M; Haebe S; Passerini V; Hellmuth JC; Gaitzsch E; Keay W; Tahiri N; Zoellner A; Rosenwald A; Klapper W; Stein H; Feller A; Ott G; Staiger AM; Horn H; Hansmann ML; Pott C; Unterhalt M; Schmidt C; Dreyling M; Alizadeh AA; Hiddemann W; Hoster E; Weigert O
    Blood Adv; 2020 Sep; 4(18):4451-4462. PubMed ID: 32941649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in the therapy of stage III and IV follicular lymphoma: Results of the REFLECT 1 study of the Serbian Lymphoma Group.
    Popovic S; Jovanovic D; Mihaljevic B; Andjelkovic N; Marjanovic G; Marisavljevic D; Vlaisavljevic N; Popovic L; Salma S; Agic D; Milosevic R; Smiljanic M; Sretenović S; Djurdjević P; Markovic O; Hajder J; Govedarovic N
    J BUON; 2017; 22(2):487-494. PubMed ID: 28534374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic Significance of Follicular Lymphoma International Prognostic Index 2 (FLIPI2) in Follicular Lymphoma Patients Treated with Rituximab Maintenance].
    Xu PP; Qian Y; Chen QS; Li LQ; Zhang L; Zhao WL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):426-430. PubMed ID: 28446287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.
    Mir F; Mattiello F; Grigg A; Herold M; Hiddemann W; Marcus R; Seymour JF; Bolen CR; Knapp A; Nielsen T; Casulo C
    Am J Hematol; 2020 Dec; 95(12):1503-1510. PubMed ID: 32815559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of age on clinical risk scores in follicular lymphoma.
    Alig S; Jurinovic V; Pastore A; Haebe S; Schmidt C; Zoellner AK; Dreyling M; Unterhalt M; Hoster E; Hiddemann W; Weigert O
    Blood Adv; 2019 Apr; 3(7):1033-1038. PubMed ID: 30940638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study.
    Madsen C; Clausen MR; Plesner TL; Pasanen A; Kuismanen T; Bentzen HH; Jørgensen JM; Sillesen IB; Himmelstrup BM; Rønnov-Jessen D; Jensen KR; Pettinger AM; Ludvigsen M; Leppä S; d'Amore FA
    Blood Adv; 2018 Jul; 2(13):1562-1571. PubMed ID: 29976619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
    Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
    Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.